文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

长效卡博特韦暴露前预防中前瞻性HIV RNA筛查:HPTN 083开放标签延长研究

Prospective HIV RNA Screening With Long-acting Cabotegravir Pre-exposure Prophylaxis in HPTN 083.
PubMed 文献 · Clin Infect Dis · 2026-01-01

BACKGROUND: Pre-exposure prophylaxis (PrEP) is highly effective for human immunodeficiency virus (HIV) prevention. However, breakthrough infections can occur, even with optimal adherence.…

要点

  • RNA筛查减少诊断延迟和耐药,但阳性预测值低,需谨慎解读阳性结果。
  • 注射CAB-LA不足6个月时RNA筛查阳性预测值仅29%,假阳性风险更高。
  • 部分假阳性RNA结果导致CAB-LA注射延迟或停止,需权衡获益与风险。

核心结论

  • HIV RNA筛查改善了CAB-LA PrEP使用者的临床结局(减少诊断延迟、提早治疗),但RNA筛查的阳性预测值低,可能影响患者照护。

研究设计与样本

  • HPTN 083开放标签延长研究,纳入使用长效注射卡博特韦暴露前预防的顺性别男性和跨性别女性,每次访视进行HIV快速抗原/抗体和RNA检测,结合回顾性检测确定最终HIV状态和首次阳性访视。

主要发现

  • 5例仅通过RNA检测首次发现HIV感染。
  • RNA检测敏感性93%(95%CI: 76, 99),特异性99.92%(95%CI: 99.88, 99.95);总体阳性预测值55%(95%CI: 40, 69),若CAB-LA给药不足6个月前则阳性预测值29%(95%CI: 13, 49)。

关键数值与推荐

  • RNA检测敏感性93%(95%CI: 76, 99),特异性99.92%(95%CI: 99.88, 99.95)。
  • 总体阳性预测值55%(95%CI: 40, 69);CAB-LA给药不足6个月时阳性预测值29%(95%CI: 13, 49)。

临床怎么用

  • 在CAB-LA PrEP随访中可考虑纳入HIV RNA筛查以尽早发现突破性感染并减少耐药。
  • 对RNA阳性结果需结合流行病学和近期CAB-LA注射史谨慎评估,避免仅凭低阳性预测值的RNA结果中断PrEP。

局限性

  • 部分假阳性RNA检测结果导致CAB-LA注射延迟或停止,可能影响患者照护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pre-exposure prophylaxis (PrEP) is highly effective for human immunodeficiency virus (HIV) prevention. However, breakthrough infections can occur, even with optimal adherence. We evaluated the performance of prospective HIV ribonucleic acid (RNA) screening in cisgender men and transgender women who have sex with men using long-acting injectable cabotegravir (CAB-LA) PrEP in HIV Prevention Trials Network (HPTN) 083. METHODS: In the Open Label Extension of HPTN 083, sites performed HIV rapid antigen/antibody (Ag/Ab) and RNA testing at each visit. Results from site testing and retrospective HIV testing were used to determine final HIV status and identify the first HIV-positive visit. RESULTS: HIV RNA screening was associated with fewer diagnostic delays (7% vs 47% of cases, P = .02) and earlier treatment initiation (median 15 vs 62 days, P = .02). Drug resistance was less frequent with RNA screening (15% vs 31% of cases, P = .22). Five cases were first detected with RNA testing only. Sensitivity and specificity of RNA testing were 93% (95% CI: 76, 99) and 99.92% (95% CI: 99.88, 99.95), respectively. However, positive predictive value (PPV) was low overall (55%; 95% CI: 40, 69) and was lower if CAB-LA was administered <6 months earlier (29%; 95% CI: 13, 49). Some false-positive RNA test results led to delay or discontinuation of CAB-LA injections. CONCLUSIONS: HIV RNA screening improved clinical outcomes in the setting of CAB-LA PrEP, but the PPV for RNA screening was low which could compromise patient care.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Landovitz RJ, Fogel JM, Gao F, et al. Prospective HIV RNA Screening With Long-acting Cabotegravir Pre-exposure Prophylaxis in HPTN 083. Clin Infect Dis. 2026. PMID: 42044061. doi:10.1093/cid/ciag285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。